Home › Funds › Two Seas Capital LP › ABUS
Two Seas Capital LP position in ABUS
ARBUTUS BIOPHARMA CORP · Health Care
Two Seas Capital LP reported holding 8,143,994 shares of ABUS (ARBUTUS BIOPHARMA CORP) in its Q3 2026 13F filing — a position valued at US$38.9M, representing 0.51% of its reported portfolio and ranking #22 among its reported holdings. Two Seas Capital LP has disclosed ABUS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Two Seas Capital LP's ABUS position evolved
Two Seas Capital LP first disclosed a stake in ABUS in Q3 2023 at 8,280,818 shares (US$16.8M). The position peaked in Q2 2026 at 19,095,583 shares, worth US$91.7M. Across 13 filings, Two Seas Capital LP increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 8,143,994 shares valued at US$38.9M — a reduction of -10,951,589 shares quarter over quarter.. Notable position changes include a 47% increase in Q1 2026 (shares rose 7% over the following quarter), a 57% trim in Q3 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 8.28M | $16.81M | New |
| Q4 2023 | 9.04M | $22.60M | Add |
| Q1 2024 | 7.84M | $20.23M | Reduce |
| Q2 2024 | 8.57M | $26.49M | Add |
| Q3 2024 | 8.39M | $32.29M | Reduce |
| Q4 2024 | 8.74M | $28.58M | Add |
| Q1 2025 | 9.47M | $33.04M | Add |
| Q2 2025 | 10.44M | $32.27M | Add |
| Q3 2025 | 10.99M | $49.90M | Add |
| Q4 2025 | 12.59M | $60.55M | Add |
| Q1 2026 | 18.56M | $83.51M | Add |
| Q2 2026 | 19.10M | $91.66M | Add |
| Q3 2026 | 8.14M | $38.93M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABUS and 13F data
ABUS (ARBUTUS BIOPHARMA CORP) is a Health Care company. 43 other funds we track also report a position in ABUS — the largest reported positions include Whitefort Capital Management, LP (US$75.8M), BlackBarn Capital Partners LP (US$12.0M), Deltroit Asset Management (UK) LLP (US$5.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABUS
- Whitefort Capital Management, LP 15.79M sh · $75.81M · Q2 2026
- BlackBarn Capital Partners LP 2.50M sh · $12.00M · Q2 2026
- Deltroit Asset Management (UK) LLP 1.20M sh · $5.76M · Q2 2026
- Western Standard LLC 542.79K sh · $2.61M · Q2 2026
- Rangeley Capital, LLC 500.00K sh · $2.40M · Q2 2026
More on Two Seas Capital LP
FAQ
How long has Two Seas Capital LP held ABUS?
Two Seas Capital LP has disclosed ABUS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Two Seas Capital LP's current position in ABUS?
As of Q3 2026, Two Seas Capital LP holds 8.14M shares of ABUS (ARBUTUS BIOPHARMA CORP), valued at $38.93M, representing 0.51% of its reported portfolio and ranking #22.
Has Two Seas Capital LP been buying or selling ABUS?
In the latest 13F filing (Q3 2026), Two Seas Capital LP reduced its position in ABUS. The position peaked in Q2 2026 at 19.10M shares.
Which other funds hold ABUS?
Other major institutional holders of ABUS include Whitefort Capital Management, LP, BlackBarn Capital Partners LP, Deltroit Asset Management (UK) LLP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.